Navigation Links
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
Date:5/19/2008

ds commercialization."

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. James Marsden and Ashley & Jeffrey McDermott to Receive Honors at the Tourette Syndrome Association 2008 Champion of Children Awards Dinner
4. Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Childrens Hospital at Stanford
5. Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs
6. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
7. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
8. Pennsylvania Invests $12.5 Million to Kick Off Williamsport Hospital Project
9. Texas Senator Tommy Williams Honored as Champion for Children by the AMERIGROUP Foundation
10. Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure
11. Vanessa Williams and Carmen Marc Valvo Make It Fashionable to Talk About Colon Cancer In New Public Service Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 ... ) investigation, Bernstein Liebhard LLP has been closely ... & Drug Administration’s (FDA) Obstetrics and Gynecology ... ways to mitigate the cancer risks associated with ... gynecological surgeries. According to a report published by ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... ... groundbreaking topic of Alzheimer,s prevention. , ... Naples, FL (PRWEB) November 12, 2009 -- Integrative neurologist, ... Advanced Neurotechnologies on the topic of Alzheimer,s disease prevention. The conference will be held ...
... ... Policy, Compliance, Risk, SOX, Internal Audits and IT Governance programs for the healthcare ... ... market leader in the enterprise-wide Governance, Risk and Compliance (“GRC”) solutions, ...
... ... AMD Patients with New Epimacular Brachytherapy System , ... Fremont, CA and Pisa, Italy (PRWEB) November 12, 2009 ... the commercialization of the VIDON® ANV® Therapy System, the company,s novel device for treating ...
... 12 ULURU Inc. (NYSE Alternext: ULU), ... a portfolio of wound management and oral care products, today ... shares of its common stock at a price per share ... investors, resulting in gross proceeds of approximately $1.5 million. , ...
... WARSAW, Ind., Nov. 12 Zimmer Holdings, ... has filed with the Securities and Exchange Commission an automatic shelf ... an unspecified amount of equity and debt securities and that it ... senior notes of a benchmark size. , The Company intends ...
... a pioneer in the development of novel products to ... has announced that it has filed its first IND ... Drug Administration (FDA). CEQ508, an orally administered ... implicated in the formation of colonic polyps and in ...
Cached Medicine News:Health News: Integrative Neurologist Breaks Ground in Alzheimer's Prevention 2Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 3Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Laser System features a patented technique for ... It selectively targets pigmented cells and increases ... II is equipped with a Q-switch that ... which induces the same cell replacement mechanism ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: